Poland: NIK report highlights genetic testing access and glioma treatment advances

A report by the Supreme Audit Office (NIK) reveals that access to genetic testing in Poland has declined between 2022 and 2025. Despite the clinical importance of genetic research, the NIK noted that legislative regulations for this sector have not been resolved since 2013. Nationally, waiting times for genetic clinics increased from an average of 115 days in 2022 to 223 days in 2025, with urgent cases rising from 48 to 124 days.

In contrast, the Oncology Center in Bydgoszcz received a positive evaluation from NIK auditors. The facility maintained shorter waiting times than the national average, with stable cases waiting approximately 100 days and urgent cases 79 days in 2025. Auditors found no irregularities in the center’s standards or the implementation of genetic testing procedures.

In medical developments, the drug Vorasidenib is offering new hope for patients with grade 2 gliomas carrying the IDH mutation. Clinical data indicates the treatment can extend progression-free survival, with some studies showing a median of 44.1 months. In Poland, the procedure to fund this medication is currently underway, potentially benefiting 150 to 200 patients annually.